OZAGREL

Details

Stereochemistry	ACHIRAL
Molecular Formula	C13H12N2O2
Molecular Weight	228.2466
Optical Activity	NONE
Defined Stereocenters	0 / 0
E/Z Centers	1
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

OC(=O)\C=C\C1=CC=C(CN2C=CN=C2)C=C1

InChI

InChIKey=SHZKQBHERIJWAO-AATRIKPKSA-N

InChI=1S/C13H12N2O2/c16-13(17)6-5-11-1-3-12(4-2-11)9-15-8-7-14-10-15/h1-8,10H,9H2,(H,16,17)/b6-5+

HIDE SMILES / InChI

Molecular Formula	C13H12N2O2
Molecular Weight	228.2466
Charge	0
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	1
Optical Activity	NONE

Description
Sources: http://www.pathophysiologyjournal.com/article/S0928-4680(97)00013-8/pdf | http://www.ncbi.nlm.nih.gov/pubmed/14720071 | http://www.ncbi.nlm.nih.gov/pubmed/7758058

Ozagrel is a thromboxane A2 synthesis inhibitor used for the treatment of cerebral vasospasm and asthma due to its antiplatelet and anti-inflammation properties.

CNS Activity

Originator

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
Thromboxane-A synthase 21 Target ID: P24557\|\|\|Q8IUN1\|\|\|Q9HD82 Gene ID: 6916.0 Gene Symbol: TBXAS1 Target Organism: Homo sapiens (Human) Sources: http://www.ncbi.nlm.nih.gov/pubmed/14720071	Inhibitor 8297		11.0 nM [IC50]

Conditions

Condition	Modality	Targets	Highest Phase	Product
Bronchial asthma 50 Sources: http://onlinelibrary.wiley.com/doi/10.1111/j.1440-1843.2006.00920_6.x/pdf	Palliative		Approved 8429	DOMENAN Approved Use Unknown
Cerebral vasospasm 9 Sources: http://apps.who.int/medicinedocs/index/assoc/h5778e/h5778e.pdf	Primary		Approved 8429	XANBON Approved Use Cerebral vasospasm and ischaemia following surgical management of subarachnoid haemorrhage.

PubMed

Title	Date	PubMed
Thromboxane A2 and development of genetic hypertension in the Lyon rat strain.	1990 Dec	2147173
Heparin-protamine complexes cause pulmonary hypertension in goats.	1995 Oct	7574058
Effect of sodium ozagrel on the activity of rat CYP2D6.	2007 Nov 14	17651725
Thromboxane synthase mutations in an increased bone density disorder (Ghosal syndrome).	2008 Mar	18264100

Patents

Sample Use Guides

In Vivo Use Guide

1 tablet (200 mg of the active ingredient) at a time, twice a day after breakfast and before bedtime (for asthma). Intravenous infusion of 80mg, twice a day, solute in 500ml normal saline or 5% glucose solution (cerebral vasospasm).

Route of Administration: Other

In Vitro Use Guide

The inﬂuence of ozagrel on platelets aggregation was investigated. Platelet aggregation which was induced by ADP (5 uM) was inhibited by ozagrel. This inhibition was dependent on the concentration of the drug and was significant at 10(−6)–10(−3) M.

Substance Class	Chemical Created by `admin` on `Sat Dec 16 17:35:39 GMT 2023` Edited by `admin` on `Sat Dec 16 17:35:39 GMT 2023`
Record UNII	L256JB984D
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

OZAGREL

Official Name

English

(E)-P-(IMIDAZOL-1-YLMETHYL)CINNAMIC ACID

Common Name

English

OZAGREL [MI]

Common Name

English

Ozagrel [WHO-DD]

Common Name

English

ozagrel [INN]

Common Name

English

OZAGREL [MART.]

Common Name

English

KCT-0809

Code

English

Classification Tree Code System Code

NCI_THESAURUS

C471